Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Recapitalization Becomes A Better Alternative In A Weak Economy

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotechs face the new reality that recapitalization may be the only route to new funding when development plans go off track due to the constricted capital markets.

You may also be interested in...

CeNeRx Completes Series C To Fund Trial; Find Partner

The biopharma raises a third round of financing to help finish a mid-stage trial for its antidepressant TriRima.

Top Partnering Opportunities In Neuroscience: The Ugly Truth

Consultant notes some promising candidates in a challenging space for investment.

Zelos Becoms Azelon; Restructures To Close A Series A

The osteoporosis drug company has revamped its focus and brought in new investors as it pushes forward with its nasal spray for osteoporosis.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts